Compare Ford Motor Company (F) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs ResMed Inc. — how do they compare? Ford Motor Company trades at $14.12 (market cap $56.50B), while ResMed Inc. trades at $200.06 (market cap $28.80B). The key difference: Ford Motor Company is the larger of the two by market cap, and Ford Motor Company pays the higher dividend (4.23%). Which is the better fit depends on your goals.
| F | RMD | |
|---|---|---|
Market Cap | $56.50B | $28.80B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $293.73 |
52-Week Low | $10.82 | $182.82 |
Enterprise Value | $185.53B | $27.99B |
Dividend Yield | 4.23% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $14.09, up 1.15% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.00. Recent earnings show volatility with Q1 2026 beating expectations but Q4 2025 missing, while revenue grew to $187.27 billion in 2025. The company maintains strong cash flow from operations at $21.28 billion and announced a $0.15 dividend for H1 2026, though net income was negative at -$8.18 billion due to high costs.
Ford's outlook is mixed, with opportunities from EV expansion and labor stability, but risks include profit margin pressure and rising debt. Analysts are cautiously optimistic with 34% buy ratings, yet investors should weigh competitive threats and macroeconomic headwinds against the stock's low P/E of 11.84 and dividend yield.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
